AI

Itsitcencloit Expands Pharmaceutical and Bio AX With ‘AgentGo’

TECHWORLD ·

Itsitcencloit Expands Pharmaceutical and Bio AX With ‘AgentGo’
Jo Sang-cheol, vice president of ITCEN CLOIT, delivers welcoming remarks at the ‘Pharmaceutical and Bio AX Transformation Seminar.’ [Photo: ITCEN CLOIT]

✦ AI Summary

Itsitcencloit said on the 20th that it would expand its AX business in the pharmaceutical and bio sector, led by its enterprise AI agent management platform, “AgentGo.”

AgentGo supports connections with existing business systems such as ERP, MES, LIMS and QMS, as well as a range of LLMs, and supports deployment on-premises, in private cloud and in public cloud environments.

The company offers features including sensitive data masking, prompt injection blocking, user-specific access control and audit logs, and has secured use cases in the pharmaceutical field for searching regulatory information by country and drafting PV plans.

BizCrushWant to follow Korean talks and live streams in real time?Try CapCrush on the web

Itsitcencloit is expanding its AX business in the pharmaceutical and bio industry with its enterprise AI agent management platform, “AgentGo,” at the forefront. On the 20th, Itsitcencloit announced that it is strengthening its AX business for the pharmaceutical and bio sector, which has high security and regulatory requirements.

The pharmaceutical and bio industry processes large volumes of data and documents throughout research and development, production, quality control and regulatory approval. At the same time, it needs to protect sensitive information and meet regulatory requirements.

For that reason, when introducing AI, key challenges for broader adoption in the field include verification systems for outputs, approval workflows and integration with existing business systems. Itsitcencloit is pursuing an AX business that links existing business systems with AI, supports practical business deployment and also supports enterprise-wide rollout.

Itsitcencloit is supporting AI use by pharmaceutical and bio companies with AgentGo at the center, tailored to that environment. AgentGo supports connections with existing business systems such as ERP, MES, LIMS and QMS, as well as various LLMs, and also supports multiple AI agents in carrying out divided tasks.

AgentGo supports deployment methods including on-premises, private cloud and public cloud. The product provides sensitive data masking, prompt injection blocking, user-specific access control and audit log functions. This allows companies to use AI agents while maintaining control over their data.

AgentGo recently obtained Grade 1 certification under GS. Based on that certification, Itsitcencloit plans to strengthen security and management features for regulated industries. It has also secured use cases in the pharmaceutical field for searching regulatory information by country and drafting PV plan documents for drug safety management.

The company plans to expand the scope of AI application, focusing on repetitive work such as regulatory response and document processing. This strategy was shared at the “Pharmaceutical and Bio AX Great Transformation Seminar: From Demo to Real Results,” held by Itsitcencloit on the 17th at the Korea Pharmaceutical and Bio-Pharma Manufacturers Association in Seocho District, Seoul.

More than 100 people in charge of pharmaceutical and bio companies attended the seminar. Discussions on regulation, security and practical business deployment in the process of introducing AI were held on site.

Speakers explained AI use in the pharmaceutical and bio sector from the perspectives of business deployment, management standards, system integration and expansion of adoption. Bae Mi-seon, CEO of Bagel, introduced examples of AI use in the RA, QA and PV fields. She also stressed that what matters is not simply reducing the time needed to draft documents, but cutting the total processing time, including final review and approval.

Lee Euigyu, a partner attorney at Barun Law LLC, explained that standards are needed for data input, judgment, approval and record management in the process of using AI. He also proposed a method of differentiating review and approval procedures according to the level of business risk.

Park So-young, an executive director at Itsitcencloit, introduced the structure linking existing business systems and AI agents using AgentGo. Park also presented application examples of AgentGo. In addition, she proposed a phased AI introduction plan that starts with a specific task and then expands to the department level and, ultimately, the entire company.

Vice President Cho Sang-cheol of Itsitcencloit pointed out that many pharmaceutical and bio companies remain stuck at the pilot stage after adopting AI because of security and regulatory burdens. He then said the company would support real-world results in pharmaceutical and bio operations with secure AI that can be used in regulated industries.

Source: TECHWORLD · Kim Seung-gi
Original: https://www.epnc.co.kr/news/articleView.html?idxno=410097

References

This article was produced with the help of an automated content generation algorithm.


Source: TECHWORLD

View original

This article was summarized and organized by BizCrush based on the original article from TECHWORLD. For exact quotations and full details, please refer to the original article.

Keep reading

BizCrush
BizCrush showing live captions over an online meeting

BizCrush app

Live captions and summaries for meetings and calls

BizCrush Inc. · CEO Taemin Kwak

HQ 100 Middlefield Rd, Menlo Park, CA 94025, USA

Korea office Z112, Room 602, 6F, 602 Yeongdong-daero, Gangnam-gu, Seoul, Republic of Korea

Support help@bizcrush.ai · Partnerships business@bizcrush.ai

AI Notice

Some features use generative AI.

Those features carry their own pre-use notice and mark AI-generated results. AI output is for reference only — always check the original source and consult an expert before making an important decision.